IMRX vs RUN · $124.2M cap vs P/E 6.0, rev $2.04B
Immuneering Corp (IMRX) versus Sunrun Inc (RUN) — a side-by-side from cached financials, not a winner call.
Immuneering Corp (IMRX) is a biotechnology company listed on US.
Sunrun Inc (RUN) is a solar company listed on NASDAQ.
Latest reported IMRX revenue for 2023-12-31 was $0. Net income was -$53.5M. Revenue was down 100.0% from 2022-12-31 to 2023-12-31. IMRX currently screens at market cap $124.2M.
Latest reported RUN revenue for 2024-12-31 was $2.04B. Net income was -$4.36B. Revenue was down 9.8% from 2023-12-31 to 2024-12-31. RUN currently screens at market cap $3.05B and trailing P/E 6.0.
IMRX currently screens at market cap $124.2M. RUN currently screens at market cap $3.05B and trailing P/E 6.0.
Not investment advice. Open the IMRX and RUN stock pages for the full models.
Not investment advice.